Findings from the ProtecT trial, the European Randomized study of Screening for Prostate Cancer, and PIVOT were among the other noteworthy studies in prostate cancer presented at the AUA annual meeting.
Kirsten Lynn Greene, MD, MSFindings from the ProtecT trial, the European Randomized study of Screening for Prostate Cancer, and PIVOT were among the other noteworthy studies in prostate cancer presented at the AUA annual meeting. The take-home messages were presented by Kirsten Lynn Greene, MD, MS, of the University of California, San Francisco.
Studies of blood and urine markers and multiparametric magnetic resonance imaging (mpMRI) for risk stratification are suggesting strategies for sequencing these tools and using their results to guide biopsy decisions.
Prostate Prognostic Grade Groups are predictive of oncologic endpoints after radical prostatectomy.
Studies investigating the impact of U.S. Preventive Services Task Force prostate cancer screening recommendations show an increased risk in high-grade disease, a decrease in diagnosis of low-risk disease, and about a 3% increase in metastasis at presentation.
Results from large trials investigating MRI fusion biopsy show no difference between visual estimation (cognitive fusion) and fusion software-based technology; mpMRI fusion performs better at overall detection versus transrectal ultrasound biopsy alone, but the two techniques are equal for detecting high-risk disease. PIRADS ≥3 is significantly associated with detection of cancer on biopsy.
Both transperineal and transrectal biopsy approaches can be done with mpMRI cognitive fusion or fusion software.
Subscribe to Urology Times to get monthly news from the leading news source for urologists.